世界のオルニチントランスカルバミラーゼ欠損症治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Ornithine Transcarbamylase Deficiency Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5918
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、95ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、オルニチントランスカルバミラーゼ欠損症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、静脈注射）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・オルニチントランスカルバミラーゼ欠損症治療の市場動向
・企業の競争状況、市場シェア
・オルニチントランスカルバミラーゼ欠損症治療の種類別市場規模と予測2016-2027（経口、静脈注射）
・オルニチントランスカルバミラーゼ欠損症治療の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局）
・オルニチントランスカルバミラーゼ欠損症治療の北米市場規模2016-2027（アメリカ、カナダ）
・オルニチントランスカルバミラーゼ欠損症治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・オルニチントランスカルバミラーゼ欠損症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・オルニチントランスカルバミラーゼ欠損症治療の中南米市場規模2016-2027（メキシコ、ブラジル）
・オルニチントランスカルバミラーゼ欠損症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Abbott Laboratories、Nutricia (Danone Group)、Mead Johnson (Reckitt Benckiser)、Horizon Therapeutics、Nestle、Bausch Health Companies、Ultragenyx Pharmaceutical、Arcturus Therapeutics、Acer Therapeutics）
・結論

Ornithine transcarbamylase (OTC) deficiency is a genetic disorder arising due to inadequate levels of OTC, an enzyme that helps decompose and eliminate unwanted nitrogen from the human body. This process is also known as the urea cycle. Deficiency of this enzyme causes excessive nitrogen accumulation, or hyperammonemia, in the blood. Another perilous effect of this genetic disorder is the secretion of elevated levels of ammonia, which is a notorious neurotoxin. Once it reaches the central nervous system, it induces symptoms such as anorexia and overall lethargy.

Market Analysis and Insights: Global Ornithine Transcarbamylase Deficiency Treatment Market
The global Ornithine Transcarbamylase Deficiency Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Ornithine Transcarbamylase Deficiency Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Ornithine Transcarbamylase Deficiency Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Ornithine Transcarbamylase Deficiency Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Ornithine Transcarbamylase Deficiency Treatment market.

Global Ornithine Transcarbamylase Deficiency Treatment Scope and Market Size
Ornithine Transcarbamylase Deficiency Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Ornithine Transcarbamylase Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oral
Intravenous

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott Laboratories
Nutricia (Danone Group)
Mead Johnson (Reckitt Benckiser)
Horizon Therapeutics
Nestle
Bausch Health Companies
Ultragenyx Pharmaceutical
Arcturus Therapeutics
Acer Therapeutics

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ornithine Transcarbamylase Deficiency Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral
1.2.3 Intravenous
1.3 Market by Application
1.3.1 Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Ornithine Transcarbamylase Deficiency Treatment Market Perspective (2016-2027)
2.2 Ornithine Transcarbamylase Deficiency Treatment Growth Trends by Regions
2.2.1 Ornithine Transcarbamylase Deficiency Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Ornithine Transcarbamylase Deficiency Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Ornithine Transcarbamylase Deficiency Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Ornithine Transcarbamylase Deficiency Treatment Industry Dynamic
2.3.1 Ornithine Transcarbamylase Deficiency Treatment Market Trends
2.3.2 Ornithine Transcarbamylase Deficiency Treatment Market Drivers
2.3.3 Ornithine Transcarbamylase Deficiency Treatment Market Challenges
2.3.4 Ornithine Transcarbamylase Deficiency Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Ornithine Transcarbamylase Deficiency Treatment Players by Revenue
3.1.1 Global Top Ornithine Transcarbamylase Deficiency Treatment Players by Revenue (2016-2021)
3.1.2 Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Ornithine Transcarbamylase Deficiency Treatment Revenue
3.4 Global Ornithine Transcarbamylase Deficiency Treatment Market Concentration Ratio
3.4.1 Global Ornithine Transcarbamylase Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ornithine Transcarbamylase Deficiency Treatment Revenue in 2020
3.5 Ornithine Transcarbamylase Deficiency Treatment Key Players Head office and Area Served
3.6 Key Players Ornithine Transcarbamylase Deficiency Treatment Product Solution and Service
3.7 Date of Enter into Ornithine Transcarbamylase Deficiency Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Ornithine Transcarbamylase Deficiency Treatment Breakdown Data by Type
4.1 Global Ornithine Transcarbamylase Deficiency Treatment Historic Market Size by Type (2016-2021)
4.2 Global Ornithine Transcarbamylase Deficiency Treatment Forecasted Market Size by Type (2022-2027)

5 Ornithine Transcarbamylase Deficiency Treatment Breakdown Data by Application
5.1 Global Ornithine Transcarbamylase Deficiency Treatment Historic Market Size by Application (2016-2021)
5.2 Global Ornithine Transcarbamylase Deficiency Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Ornithine Transcarbamylase Deficiency Treatment Market Size (2016-2027)
6.2 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type
6.2.1 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021)
6.2.2 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027)
6.2.3 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2027)
6.3 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application
6.3.1 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021)
6.3.2 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027)
6.3.3 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2027)
6.4 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country
6.4.1 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2016-2021)
6.4.2 North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size (2016-2027)
7.2 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Type
7.2.1 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021)
7.2.2 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027)
7.2.3 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2027)
7.3 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Application
7.3.1 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021)
7.3.2 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027)
7.3.3 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2027)
7.4 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Country
7.4.1 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2016-2021)
7.4.2 Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size (2016-2027)
8.2 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Type
8.2.1 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Application
8.3.1 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Region
8.4.1 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size (2016-2027)
9.2 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type
9.2.1 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2027)
9.3 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application
9.3.1 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2027)
9.4 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country
9.4.1 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size (2016-2027)
10.2 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Type
10.2.1 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Application
10.3.1 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Country
10.4.1 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Introduction
11.1.4 Abbott Laboratories Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.1.5 Abbott Laboratories Recent Development
11.2 Nutricia (Danone Group)
11.2.1 Nutricia (Danone Group) Company Details
11.2.2 Nutricia (Danone Group) Business Overview
11.2.3 Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Introduction
11.2.4 Nutricia (Danone Group) Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.2.5 Nutricia (Danone Group) Recent Development
11.3 Mead Johnson (Reckitt Benckiser)
11.3.1 Mead Johnson (Reckitt Benckiser) Company Details
11.3.2 Mead Johnson (Reckitt Benckiser) Business Overview
11.3.3 Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Introduction
11.3.4 Mead Johnson (Reckitt Benckiser) Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.3.5 Mead Johnson (Reckitt Benckiser) Recent Development
11.4 Horizon Therapeutics
11.4.1 Horizon Therapeutics Company Details
11.4.2 Horizon Therapeutics Business Overview
11.4.3 Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Introduction
11.4.4 Horizon Therapeutics Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.4.5 Horizon Therapeutics Recent Development
11.5 Nestle
11.5.1 Nestle Company Details
11.5.2 Nestle Business Overview
11.5.3 Nestle Ornithine Transcarbamylase Deficiency Treatment Introduction
11.5.4 Nestle Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.5.5 Nestle Recent Development
11.6 Bausch Health Companies
11.6.1 Bausch Health Companies Company Details
11.6.2 Bausch Health Companies Business Overview
11.6.3 Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Introduction
11.6.4 Bausch Health Companies Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.6.5 Bausch Health Companies Recent Development
11.7 Ultragenyx Pharmaceutical
11.7.1 Ultragenyx Pharmaceutical Company Details
11.7.2 Ultragenyx Pharmaceutical Business Overview
11.7.3 Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Introduction
11.7.4 Ultragenyx Pharmaceutical Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.7.5 Ultragenyx Pharmaceutical Recent Development
11.8 Arcturus Therapeutics
11.8.1 Arcturus Therapeutics Company Details
11.8.2 Arcturus Therapeutics Business Overview
11.8.3 Arcturus Therapeutics Ornithine Transcarbamylase Deficiency Treatment Introduction
11.8.4 Arcturus Therapeutics Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.8.5 Arcturus Therapeutics Recent Development
11.9 Acer Therapeutics
11.9.1 Acer Therapeutics Company Details
11.9.2 Acer Therapeutics Business Overview
11.9.3 Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Introduction
11.9.4 Acer Therapeutics Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
11.9.5 Acer Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Ornithine Transcarbamylase Deficiency Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral
Table 3. Key Players of Intravenous
Table 4. Global Ornithine Transcarbamylase Deficiency Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Ornithine Transcarbamylase Deficiency Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Ornithine Transcarbamylase Deficiency Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Regions (2016-2021)
Table 8. Global Ornithine Transcarbamylase Deficiency Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Regions (2022-2027)
Table 10. Ornithine Transcarbamylase Deficiency Treatment Market Trends
Table 11. Ornithine Transcarbamylase Deficiency Treatment Market Drivers
Table 12. Ornithine Transcarbamylase Deficiency Treatment Market Challenges
Table 13. Ornithine Transcarbamylase Deficiency Treatment Market Restraints
Table 14. Global Ornithine Transcarbamylase Deficiency Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Players (2016-2021)
Table 16. Global Top Ornithine Transcarbamylase Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ornithine Transcarbamylase Deficiency Treatment as of 2020)
Table 17. Ranking of Global Top Ornithine Transcarbamylase Deficiency Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Ornithine Transcarbamylase Deficiency Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Ornithine Transcarbamylase Deficiency Treatment Product Solution and Service
Table 21. Date of Enter into Ornithine Transcarbamylase Deficiency Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global Ornithine Transcarbamylase Deficiency Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Ornithine Transcarbamylase Deficiency Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global Ornithine Transcarbamylase Deficiency Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Abbott Laboratories Company Details
Table 62. Abbott Laboratories Business Overview
Table 63. Abbott Laboratories Ornithine Transcarbamylase Deficiency Treatment Product
Table 64. Abbott Laboratories Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 65. Abbott Laboratories Recent Development
Table 66. Nutricia (Danone Group) Company Details
Table 67. Nutricia (Danone Group) Business Overview
Table 68. Nutricia (Danone Group) Ornithine Transcarbamylase Deficiency Treatment Product
Table 69. Nutricia (Danone Group) Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 70. Nutricia (Danone Group) Recent Development
Table 71. Mead Johnson (Reckitt Benckiser) Company Details
Table 72. Mead Johnson (Reckitt Benckiser) Business Overview
Table 73. Mead Johnson (Reckitt Benckiser) Ornithine Transcarbamylase Deficiency Treatment Product
Table 74. Mead Johnson (Reckitt Benckiser) Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 75. Mead Johnson (Reckitt Benckiser) Recent Development
Table 76. Horizon Therapeutics Company Details
Table 77. Horizon Therapeutics Business Overview
Table 78. Horizon Therapeutics Ornithine Transcarbamylase Deficiency Treatment Product
Table 79. Horizon Therapeutics Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 80. Horizon Therapeutics Recent Development
Table 81. Nestle Company Details
Table 82. Nestle Business Overview
Table 83. Nestle Ornithine Transcarbamylase Deficiency Treatment Product
Table 84. Nestle Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 85. Nestle Recent Development
Table 86. Bausch Health Companies Company Details
Table 87. Bausch Health Companies Business Overview
Table 88. Bausch Health Companies Ornithine Transcarbamylase Deficiency Treatment Product
Table 89. Bausch Health Companies Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 90. Bausch Health Companies Recent Development
Table 91. Ultragenyx Pharmaceutical Company Details
Table 92. Ultragenyx Pharmaceutical Business Overview
Table 93. Ultragenyx Pharmaceutical Ornithine Transcarbamylase Deficiency Treatment Product
Table 94. Ultragenyx Pharmaceutical Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 95. Ultragenyx Pharmaceutical Recent Development
Table 96. Arcturus Therapeutics Company Details
Table 97. Arcturus Therapeutics Business Overview
Table 98. Arcturus Therapeutics Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 99. Arcturus Therapeutics Recent Development
Table 100. Acer Therapeutics Company Details
Table 101. Acer Therapeutics Business Overview
Table 102. Acer Therapeutics Ornithine Transcarbamylase Deficiency Treatment Product
Table 103. Acer Therapeutics Revenue in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021) & (US$ Million)
Table 104. Acer Therapeutics Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Type: 2020 VS 2027
Figure 2. Oral Features
Figure 3. Intravenous Features
Figure 4. Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Application: 2020 VS 2027
Figure 5. Hospital Pharmacies Case Studies
Figure 6. Retail Pharmacies Case Studies
Figure 7. Online Pharmacies Case Studies
Figure 8. Ornithine Transcarbamylase Deficiency Treatment Report Years Considered
Figure 9. Global Ornithine Transcarbamylase Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Ornithine Transcarbamylase Deficiency Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Regions: 2020 VS 2027
Figure 12. Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Regions (2022-2027)
Figure 13. Global Ornithine Transcarbamylase Deficiency Treatment Market Share by Players in 2020
Figure 14. Global Top Ornithine Transcarbamylase Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ornithine Transcarbamylase Deficiency Treatment as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Ornithine Transcarbamylase Deficiency Treatment Revenue in 2020
Figure 16. Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share by Type (2016-2021)
Figure 17. Global Ornithine Transcarbamylase Deficiency Treatment Revenue Market Share by Type (2022-2027)
Figure 18. North America Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Ornithine Transcarbamylase Deficiency Treatment Market Share by Type (2016-2027)
Figure 20. North America Ornithine Transcarbamylase Deficiency Treatment Market Share by Application (2016-2027)
Figure 21. North America Ornithine Transcarbamylase Deficiency Treatment Market Share by Country (2016-2027)
Figure 22. United States Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Ornithine Transcarbamylase Deficiency Treatment Market Share by Type (2016-2027)
Figure 26. Europe Ornithine Transcarbamylase Deficiency Treatment Market Share by Application (2016-2027)
Figure 27. Europe Ornithine Transcarbamylase Deficiency Treatment Market Share by Country (2016-2027)
Figure 28. Germany Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Ornithine Transcarbamylase Deficiency Treatment Market Share by Region (2016-2027)
Figure 38. China Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Share by Type (2016-2027)
Figure 46. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Share by Application (2016-2027)
Figure 47. Latin America Ornithine Transcarbamylase Deficiency Treatment Market Share by Country (2016-2027)
Figure 48. Mexico Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Ornithine Transcarbamylase Deficiency Treatment Market Share by Country (2016-2027)
Figure 54. Turkey Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Ornithine Transcarbamylase Deficiency Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Abbott Laboratories Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 58. Nutricia (Danone Group) Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 59. Mead Johnson (Reckitt Benckiser) Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 60. Horizon Therapeutics Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 61. Nestle Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 62. Bausch Health Companies Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 63. Ultragenyx Pharmaceutical Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 64. Arcturus Therapeutics Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 65. Acer Therapeutics Revenue Growth Rate in Ornithine Transcarbamylase Deficiency Treatment Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Size, Status and Forecast 2021-2027
QFJ1-4628 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、オルニチントランスカルバミラーゼ（OTC）欠損症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、静脈注射）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、...

世界のオルニチン-トランスカルバミラーゼ欠損症市場規模・現状・予測（2021年-2027年）

Global Ornithine-Transcarbamylase Deficiency Market Size, Status and Forecast 2021-2027
QFJ1-4629 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、オルニチン-トランスカルバミラーゼ欠損症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（DTX-301、SEL-313、SHP-641、PRX-OTC、その他）、用途別市場規模（病院、クリニック、その...

世界のアルギナーゼ欠損症治療薬市場規模・現状・予測（2021年-2027年）

Global Arginase Deficiency Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-3850 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、アルギナーゼ欠損症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国...

世界のアルギナーゼ欠損症治療市場規模・現状・予測（2021年-2027年）

Global Arginase Deficiency Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3851 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、アルギナーゼ欠損症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、...

世界のACTH欠乏症治療市場規模・現状・予測（2021年-2027年）

Global ACTH Deficiency Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3753 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、ACTH欠乏症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（先天性、後天性）、用途別市場規模（病院、薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東...

世界のCDKL5欠乏症（CDD）市場規模・現状・予測（2021年-2027年）

Global CDKL5 Deficiency Disorder (CDD) Market Size, Status and Forecast 2021-2027
QFJ1-3983 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、CDKL5欠乏症（CDD）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（従来型医薬品、新型医薬品）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中...

世界の亜鉛欠乏症治療市場規模・現状・予測（2021年-2027年）

Global Zinc Deficiency Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5049 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、亜鉛欠乏症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口剤、注射剤）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国...

世界のα1アンチトリプシン欠乏症増強療法市場規模・現状・予測（2021年-2027年）

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, Status and Forecast 2021-2027
QFJ1-3783 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、α1アンチトリプシン欠乏症増強療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（グラシア、アララストNP、プロラスチンC、その他）、用途別市場規模（病院、専門診療所）、主要地域別市場規模（北米、アメ...

世界のビオチニダーゼ欠損症市場規模・現状・予測（2021年-2027年）

Global Biotinidase Deficiency Market Size, Status and Forecast 2021-2027
QFJ1-5622 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、ビオチニダーゼ欠損症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（重度ビオチニダーゼ欠損症、部分的ビオチニダーゼ欠損症）、用途別市場規模（病院、専門クリニック、ドラッグストア、小売薬局、オンライン薬...

世界の成長ホルモン欠乏療法市場規模・現状・予測（2021年-2027年）

Global Growth Hormone Deficiency Therapy Market Size, Status and Forecast 2021-2027
QFJ1-5761 2021年6月 119Pages
QYResearch社発行の本調査レポートでは、成長ホルモン欠乏療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（非経口、経皮、経口、その他）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本...

世界のオルニチントランスカルバミラーゼ（OTC）欠損症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market The global Ornithine Transcarbamylase (OTC) Deficiency Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-s…
世界のオルニチン-トランスカルバミラーゼ欠損症市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Ornithine-Transcarbamylase Deficiency Market The global Ornithine-Transcarbamylase Deficiency market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and…
世界の亜鉛欠乏症治療市場規模・現状・予測（2021年-2027年） Fill zinc, it is the microelement zinc that compensatory human body needs, filling zinc is in human body growth development, immunity, vitamin to wait to having extremely important effect. Market Analysis and Insights: Global Zinc Deficiency Treatment Market The global Zinc Deficiency Treatment mark…
世界のアルギナーゼ欠損症治療市場規模・現状・予測（2021年-2027年） Argininemia, also called arginase deficiency, is an autosomal recessive urea cycle disorder where adeficiency of the enzyme arginase causes a buildup of arginine and ammonia in the blood. Market Analysis and Insights: Global Arginase Deficiency Treatment Market The global Arginase Deficiency Treatme…
世界のACTH欠乏症治療市場規模・現状・予測（2021年-2027年） ACTH is an adrenocorticotropic hormone, which is a hormone secreted by the anterior pituitary gland, which can maintain the normal form and function of the adrenal glands. The main role of ACTH is to promote the secretion of glucocorticoids by the adrenal cortex, maintaining the normal physiological…